Navigation Links
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2013 and Addresses Key Questions from Investors on Quarterly Conference Call
Date:11/7/2013

s' equity:  Accounts payable and accrued liabilities$
2,730$
7,050  Current portion of long-term obligations1,0901,084  Warrant liability5483,422  Long term liabilities3,7284,253  Stockholders' equity43,54366,207Total liabilities and stockholders' equity$
,639$
82,016Conference Call Details OncoGenex will host a conference call at 4:30 p.m. Eastern Time today, Thursday, November 7, 2013, to provide a business update and discuss the third quarter 2013 results.

A live event will be available on the Investor Relations section of the OncoGenex website at www.OncoGenex.com. Alternatively, you may access the live conference call by dialing 877-606-1416 (U.S. & Canada) or 707-287-9313 (International). A replay of the webcast will be available approximately two hours after the call and will be archived for 90 days. You can also monitor key information from the conference call by following the new OncoGenex Investor Relations Twitter account at: http://twitter.com/@OncoGenex_IR.

ABOUT ONCOGENEX
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer a
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3 "SYNERGY" Study
2. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Update and Reports Financial Results for Third Quarter 2012
3. OncoGenex to Present at Credit Suisse Healthcare Investor Conference
4. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
7. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
8. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
9. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
10. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
11. FierceBiotech Names Enanta Pharmaceuticals, Inc. a Fierce 15 Winner
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 22, 2014  ( www.competitivehealth.com ) — Competitive Health ... bill review and advocacy service, has signed an agreement ... Savings discount health services marketplace. 63% of ... than they expected to pay. As part of an ... WellCard Savings is pleased to offer medical bill review ...
(Date:12/19/2014)... 2014 Charm Sciences is pleased to ... Detection of Aflatoxin M1 in raw commingled milk is ... party validation. The peer reviewed report of the validation ... for Agricultural and Fisheries Research (ILVO-T&V) has been published ... B1, the most toxic aflatoxin and a known carcinogen, ...
(Date:12/19/2014)... , Dec. 19, 2014 Decision Resources Group ... grow at a 12 percent compound annual growth rate ... the aging population and the increasing adoption of dental ... will also spur demand for dental biomaterials ... implant and periodontal treatments. Other key findings ...
(Date:12/19/2014)... Ed Bilsky, Ph.D., vice president for ... Excellence in the Neurosciences (CEN), and professor of pharmacology ... as a member of the prestigious Dana Alliance for ... Maine to receive this honor. , The Dana ... the Dana Foundation. Its mission is to advance ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 2UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 3
... Quanterix Corporation, a company enabling a new generation of ... ngle Mo lecule A rray (SiMoA ™ ... of its Prostate Specific Antigen (PSA) test, a fifth-generation ... predictor of five-year biochemical recurrence (BCR)-free survival following radical ...
... to make a highly efficient and yet cheaper silicon ... the cost of solar energy can be halved. ... Institute of Microelectronics (IME), the new thin-film silicon solar ... grade silicon. However it is able to generate electricity ...
... deCODE genetics today ... with Pfizer Inc., the objective of which is to ... to Systemic Lupus Erythematosis by utilizing deCODE,s expertise in ... extensive population and genetic resources, including DNA samples and ...
Cached Biology Technology:Quanterix PSA Test Found to be a Reliable Predictor of Prostate Cancer Recurrence Following Surgery 2Quanterix PSA Test Found to be a Reliable Predictor of Prostate Cancer Recurrence Following Surgery 3NTU and A*STAR Institute of Microelectronics develop cheaper yet efficient thin film solar cells 2deCODE Announces Agreement With Pfizer to Search for Variants in the Human Genome That Confer Risk of Systemic Lupus Erythematosis 2
(Date:12/22/2014)... , Dec. 22, 2014 Research and ... announced the addition of the "The ... to their offering. ... provides an overview of the global digital ... to control and monitor piracy by securely ...
(Date:12/19/2014)... 18, 2014 Research and Markets ( ... "Micro Market Monitor: North America Perimeter Security Systems Market" ... http://photos.prnewswire.com/prnh/20130307/600769 The North American perimeter ... of 3.6% from 2014 to 2019. Although the U.S. ... Canada is expected to grow at ...
(Date:12/17/2014)... 2014 Research and Markets ( ... "Samsung Galaxy S5 - Home Button Synaptics ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... technology than the iPhone 5S, Samsung introduces for ... product. The Galaxy S5 home button ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2
... summer for sports, fans. World records tumbled at the ... 200m world records, knocking tenths of a second off ... the last few decades, which made marathon runner Mark ... increase in population could account for these dramatic improvements. ...
... genetic polymorphisms induce major differentiations in the metabolic ... paper published November 28 in the open-access journal ... of researchers, led by Karsten Suhre, has conducted ... variants in genes involved in the breakdown of ...
... A new and insidious environmental threat has been ... Queen,s and York universities. Along with scientists ... documented biological damage caused by declining levels of ... the phenomenon "aquatic osteoporosis," Queen,s PhD candidate Adam ...
Cached Biology News:100-meter sprint world record could go as low as 9.48 seconds 2Study identifies genetic variants giving rise to differences in metabolism 2Queen's University biologists find new environmental threat in North American lakes 2
DEAD (Asp-Glu-Ala-Asp) box polypeptide 5...
...
RayBio L Series 507: RayBio Label-based Antibody Array I (1 glass slide with 2 subarrays) Class: Antibody Array Products Product Group: Antibody Array...
Rat CXCL7/Thymus Chemokine-1 DuoSet Economy Pack, 45 Plate...
Biology Products: